Zhong Guo Jing Ji Wang·2025-12-01 09:33Group 1 - The core point of the article highlights that Yahui Pharmaceutical (688176.SH) is currently trading at 9.95 yuan, reflecting a decline of 2.26% and is in a state of share price decline since its IPO [1] - Yahui Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 7, 2022, with an issuance of 110 million shares at a price of 22.98 yuan per share, underwritten by CITIC Securities [1] - The stock price fell below the IPO price on the first trading day, reaching a maximum price of 20.00 yuan, which was the highest price since its listing [1] Group 2 - The total funds raised from the initial public offering (IPO) amounted to 2.528 billion yuan, with a net amount of 2.381 billion yuan after deducting issuance costs, exceeding the original plan by 311 million yuan [1] - The funds are intended for projects including drug and medical device production, new drug research and development, marketing network construction, and working capital supplementation [1] - The total issuance costs for the IPO were 147 million yuan, with CITIC Securities receiving 130 million yuan in underwriting and sponsorship fees [1] Group 3 - The controlling shareholder and actual controller of Yahui Pharmaceutical is PAN KE, who holds American nationality and serves as the chairman and general manager of the company [1]